Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Healthcare Biotechnology Medical Instruments & Supplies
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > Spectral on Linkedin
View:
Post by TechOne on Feb 19, 2024 1:31pm

Spectral on Linkedin

Enrolling patient 90 represents a major milestone for Spectral as we continue to see acceleration across our #Tigris trial sites and building confidence and momentum towards completing the trial. Tigris represents a Phase 3 follow-on study that investigates the efficacy of Polymyxin B Hemoperfusion PMX through a randomized controlled trial involving adults undergoing treatment for endotoxemia and septic shock. Read more: https://lnkd.in/gqy3HwS5
 No alternative text description for this imageNo alternative text description for this image
Comment by BlueJays9293 on Feb 19, 2024 11:29pm
Thank you for posting that TechOne.  Kudos and cheers to hearing from Dr. Kellum.  Thank you for helping us old timers stay on top of things.
Spectral Medical Inc